August 29 | 2025 CEO Nathaniel Hutley presents a strategic update on 2cureX’s new Website Blog. Read more
August 21 | 2025 2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2025. Read more
July 2 | 2025 Correction: CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025. Read more
July 1 | 2025 2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG. Read more
May 20 | 2025 2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy Read more
May 15 | 2025 2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap Read more
January 20 | 2025 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE Read more
January 10 | 2025 Correction: 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE Read more